Study of R-ACVBP [rituximab + doxorubicin + cyclophosphamide + vindesine + bleomycin + cortisone] regimen supported by pegfilgrastim in previously untreated patients aged from 18 to 60 years with high-risk diffuse large B-cell lymphoma (age-adjusted Ipi greater than or equal to 2).
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2006
At a glance
- Drugs Bleomycin; Cortisone; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Rituximab; Vindesine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 10 Nov 2005 New trial record.